• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Clarification on the definition of complete haematologic response in light-chain (AL) amyloidosis.

作者信息

Palladini Giovanni, Schönland Stefan O, Sanchorawala Vaishali, Kumar Shaji, Wechalekar Ashutosh, Hegenbart Ute, Milani Paolo, Ando Yukio, Westermark Per, Dispenzieri Angela, Merlini Giampaolo

机构信息

Amyloidosis Research and Treatment Center, Foundation "Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Policlinico San Matteo", Department of Molecular Medicine, University of Pavia, Pavia, Italy.

Department V of Internal Medicine, Amyloidosis Center, University Hospital Heidelberg, Heidelberg, Germany.

出版信息

Amyloid. 2021 Mar;28(1):1-2. doi: 10.1080/13506129.2020.1868810. Epub 2021 Jan 7.

DOI:10.1080/13506129.2020.1868810
PMID:33410355
Abstract
摘要

相似文献

1
Clarification on the definition of complete haematologic response in light-chain (AL) amyloidosis.关于轻链（AL）淀粉样变性中完全血液学缓解定义的阐释
Amyloid. 2021 Mar;28(1):1-2. doi: 10.1080/13506129.2020.1868810. Epub 2021 Jan 7.
2
Novel challenges in the management of immunoglobulin light chain amyloidosis: from the bench to the bedside.免疫球蛋白轻链淀粉样变性管理中的新挑战：从基础到临床。
Expert Rev Hematol. 2020 Sep;13(9):1003-1015. doi: 10.1080/17474086.2020.1803060. Epub 2020 Aug 11.
3
Outcomes of patients with AL amyloidosis and low serum free light chain levels at diagnosis.诊断时血清游离轻链水平低的淀粉样变性患者的结局。
Amyloid. 2018 Sep;25(3):156-159. doi: 10.1080/13506129.2018.1490261. Epub 2018 Jul 21.
4
Localized Lymph Node Light Chain Amyloidosis.局限性淋巴结轻链淀粉样变。
Intern Med. 2020 Oct 1;59(19):2415-2418. doi: 10.2169/internalmedicine.4651-20. Epub 2020 Jun 30.
5
Stem cell transplantation for immunoglobulin light chain amyloidosis.免疫球蛋白轻链淀粉样变性的干细胞移植
Curr Probl Cancer. 2017 Mar-Apr;41(2):129-137. doi: 10.1016/j.currproblcancer.2017.03.001. Epub 2017 Mar 16.
6
High-Dose Melphalan and Stem Cell Transplantation in Patients on Dialysis Due to Immunoglobulin Light-Chain Amyloidosis and Monoclonal Immunoglobulin Deposition Disease.高剂量马法兰和干细胞移植治疗因免疫球蛋白轻链淀粉样变性和单克隆免疫球蛋白沉积病而接受透析的患者。
Biol Blood Marrow Transplant. 2018 Jan;24(1):127-132. doi: 10.1016/j.bbmt.2017.08.031. Epub 2017 Sep 1.
7
Deferred autologous stem cell transplantation in systemic AL amyloidosis.系统性淀粉样变病中的延迟自体干细胞移植。
Blood Cancer J. 2018 Nov 5;8(11):101. doi: 10.1038/s41408-018-0137-9.
8
The impact and importance of achieving a complete haematological response prior to renal transplantation in AL amyloidosis.在AL淀粉样变性患者肾移植前实现完全血液学缓解的影响及重要性。
Blood Cancer J. 2020 May 22;10(5):60. doi: 10.1038/s41408-020-0325-2.
9
Bioelectrical impedance vector analysis-derived phase angle predicts survival in patients with systemic immunoglobulin light-chain amyloidosis.生物电阻抗向量分析衍生的相位角可预测系统性免疫球蛋白轻链淀粉样变患者的生存情况。
Amyloid. 2020 Sep;27(3):168-173. doi: 10.1080/13506129.2020.1737004. Epub 2020 Mar 26.
10
Role of implantable intracardiac defibrillators in patients with cardiac immunoglobulin light chain amyloidosis.植入式心脏除颤器在心脏免疫球蛋白轻链淀粉样变患者中的作用。
Br J Haematol. 2018 Jul;182(1):145-148. doi: 10.1111/bjh.14747. Epub 2017 May 9.

引用本文的文献

1
Improved survival with daratumumab-CyBorD compared with CyBorD as frontline therapy for AL amyloidosis.与CyBorD相比，达雷妥尤单抗联合CyBorD作为一线治疗方案可提高AL淀粉样变性患者的生存率。
Blood Neoplasia. 2025 Mar 10;2(2):100092. doi: 10.1016/j.bneo.2025.100092. eCollection 2025 May.
2
Outcomes of daratumumab-bortezomib-thalidomide-dexamethasone in treatment-naive systemic AL amyloidosis.达雷妥尤单抗-硼替佐米-沙利度胺-地塞米松方案治疗初治系统性AL淀粉样变性的疗效
Br J Haematol. 2025 Apr;206(4):1141-1148. doi: 10.1111/bjh.20021. Epub 2025 Feb 21.
3
Diffuse lung involvement as a rare presentation of systemic AL amyloidosis: a retrospective cohort study.
弥漫性肺部受累作为系统性AL淀粉样变性的罕见表现：一项回顾性队列研究
Blood Adv. 2025 May 13;9(9):2221-2225. doi: 10.1182/bloodadvances.2024015646.
4
Early dFLC response by C1D7 predicts complete hematologic response in systemic AL amyloidosis.C1D7引起的早期游离轻链（dFLC）反应可预测系统性AL淀粉样变性的完全血液学缓解。
Ann Hematol. 2025 Jan;104(1):617-625. doi: 10.1007/s00277-024-06077-0. Epub 2024 Nov 12.
5
Belantamab Mafodotin in Relapsed/Refractory AL Amyloidosis: Real-World Multi-Center Experience and Review of the Literature.贝兰他单抗莫福汀治疗复发/难治性轻链型淀粉样变性：真实世界多中心经验及文献综述
Acta Haematol. 2025;148(4):419-426. doi: 10.1159/000541594. Epub 2024 Oct 2.
6
Redefining Cardiac Involvement and Targets of Treatment in Systemic Immunoglobulin AL Amyloidosis.重新定义系统性免疫球蛋白 AL 淀粉样变的心脏受累和治疗靶点。
JAMA Cardiol. 2024 Nov 1;9(11):982-989. doi: 10.1001/jamacardio.2024.2555.
7
Diagnostic performance of liver stiffness as marker of liver involvement in systemic immunoglobulin light chain (AL) amyloidosis.肝脏硬度作为系统性免疫球蛋白轻链（AL）淀粉样变性中肝脏受累标志物的诊断性能。
Ann Hematol. 2025 Jan;104(1):653-663. doi: 10.1007/s00277-024-05932-4. Epub 2024 Aug 16.
8
Pathway for Development and Validation of Multi-domain Endpoints for Amyloid Light Chain (AL) Amyloidosis.多域终点在轻链淀粉样变（AL）淀粉样变性中的开发和验证途径。
Ther Innov Regul Sci. 2024 Jul;58(4):600-609. doi: 10.1007/s43441-024-00641-6. Epub 2024 Apr 17.
9
Treatment patterns for AL amyloidosis after frontline daratumumab, bortezomib, cyclophosphamide, and dexamethasone treatment failures.一线达雷妥尤单抗、硼替佐米、环磷酰胺和地塞米松治疗失败后AL淀粉样变性的治疗模式
Leukemia. 2024 Jun;38(6):1423-1426. doi: 10.1038/s41375-024-02243-5. Epub 2024 Apr 9.
10
Efficacy and safety of daratumumab plus bortezomib and dexamethasone in newly diagnosed Mayo 2004 stage IIIA or IIIB light-chain amyloidosis: a prospective phase II study.达雷妥尤单抗联合硼替佐米及地塞米松治疗新诊断的2004版梅奥分期IIIA或IIIB期轻链型淀粉样变性的疗效与安全性：一项前瞻性II期研究
Haematologica. 2024 Jul 1;109(7):2355-2358. doi: 10.3324/haematol.2024.285145.